within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH05_Naldemedine;

model Naldemedine
  extends Pharmacolibrary.Drugs.ATC.A.A06AH05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A06AH05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Naldemedine is a peripherally-acting μ-opioid receptor antagonist (PAMORA) used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. It is an approved prescription medication, generally well-tolerated, and intended for oral administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following a single oral dose of 0.2 mg.</p><h4>References</h4><ol><li><p>Fukumura, K, et al., &amp; Kawasaki, A (2020). The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. <i>Clinical pharmacology in drug development</i> 9(2) 162–174. DOI:<a href=\"https://doi.org/10.1002/cpdd.690\">10.1002/cpdd.690</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30977959/\">https://pubmed.ncbi.nlm.nih.gov/30977959</a></p></li><li><p>Fukumura, K, et al., &amp; Ogura, E (2020). Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects. <i>Clinical drug investigation</i> 40(6) 529–540. DOI:<a href=\"https://doi.org/10.1007/s40261-020-00902-w\">10.1007/s40261-020-00902-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32323104/\">https://pubmed.ncbi.nlm.nih.gov/32323104</a></p></li><li><p>Ohnishi, S, et al., &amp; Wajima, T (2019). Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(9) 1044–1053. DOI:<a href=\"https://doi.org/10.1080/00498254.2018.1536815\">10.1080/00498254.2018.1536815</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30351180/\">https://pubmed.ncbi.nlm.nih.gov/30351180</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Naldemedine;
